Incidence and Predictive Risk Factors of Infective Events in Patients With Multiple Sclerosis Treated With Agents Targeting CD20 and CD52 Surface Antigens | Zendy

Emanuela Zappulo | Zendy; Antonio Riccardo Buonomo | Zendy; Francesco Saccà | Zendy; Cinzia Valeria Russo | Zendy; Riccardo Scotto | Zendy; Giulia Scalia | Zendy; Agostino Nozzolillo | Zendy; Roberta Lanzillo | Zendy; Grazia Tosone | Zendy; Ivan Gentile | Zendy

Open Access

Incidence and Predictive Risk Factors of Infective Events in Patients With Multiple Sclerosis Treated With Agents Targeting CD20 and CD52 Surface Antigens

Author(s) -

Emanuela Zappulo,

Antonio Riccardo Buonomo,

Francesco Saccà,

Cinzia Valeria Russo,

Riccardo Scotto,

Giulia Scalia,

Agostino Nozzolillo,

Roberta Lanzillo,

Grazia Tosone,

Ivan Gentile

Publication year - 2019

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofz445

Subject(s) - cd52 , alemtuzumab , medicine , incidence (geometry) , hazard ratio , multiple sclerosis , rituximab , immunology , cd20 , confidence interval , lymphoma , transplantation , physics , optics

Given their considerable infection risk, MS patients receiving MAbs should undergo timely follow up and tailored preventive interventions. Anti-CD52-based treatment, prior exposure to MS drugs, and on-treatment immune impairment are significant predictive factors of infection and their evaluation could help clinicians to stratify a patient's risk of infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research